.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent oncological research highlights the pivotal role of CHD4 in tumor progression and its complex function within the nucleosome-remodeling and deacetylase (NuRD) complex. As a core ATP-dependent factor, CHD4 governs essential cellular processes like gene expression and DNA damage response. Interestingly, its function depends heavily on the specific tumor environment. While it often drives cancer development, it can also act as a tumor suppressor in certain transcriptional settings. Consequently, understanding these dual roles is vital for developing effective oncology treatments.
Furthermore, CHD4 significantly influences tumor growth by regulating key signaling pathways and maintaining the silencing of tumor suppressor genes. This protein also promotes metabolic adaptation, which helps cancer cells survive under metabolic stress. Beyond its role in growth, CHD4 is a critical player in the DNA damage response (DDR). It facilitates chromatin remodeling at damage sites and assists in cell cycle recovery. Moreover, it guides the selection of specific repair pathways, ensuring genomic stability even during therapeutic stress.
However, the most challenging aspect involves its contribution to treatment resistance. CHD4 helps tumor cells evade the effects of chemotherapy and radiation through several distinct mechanisms. For instance, it regulates drug efflux and stabilizes replication forks during DNA synthesis. Additionally, it alters the tumor immune microenvironment to protect malignant cells from immune detection. Because various non-coding RNAs modulate its stability and localization, CHD4 serves as a central hub for therapeutic evasion. Therefore, targeting this protein could potentially reverse resistance and improve clinical outcomes for cancer patients.
CHD4 is a chromatin-remodeling factor that regulates gene expression and DNA repair. It can either promote tumor growth or suppress it, depending on the specific cellular and transcriptional context.
It promotes resistance by enhancing DNA repair efficiency, increasing drug efflux, and stabilizing replication forks, which allows cancer cells to survive intensive therapy.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A review of CHD4's dual role in cancer, highlighting its impact on chromatin remodeling, DNA repair, and its contribution to treatment resistance....
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
